![]() To drive purposeful change in biopharmaceutical R&D, it’s not enough to create solutions aimed at streamlining operations and adopting new technologies-solutions must be acceptable to, and supported by, the intended users. The lack of diversity in clinical trials remains a key barrier in achieving equitable health outcomes for all. ![]() When I think of diversity, I consider three different aspects: geographical regions, socioeconomic groups, and ethnic and racial backgrounds. The global COVID-19 pandemic and the continued response to social injustice have activated people from all parts of the world to respond with heart and humanity and seek steps to drive change. As a professional in the healthcare ecosystem, it’s been promising to see this surfacing as a high priority within the clinical research community in the past two years. Jul 28 Clinical Study Reports for Studies Impacted by COVID-19: Key Considerationsĭiversity and Inclusion (D&I) are top of mind for everyone these days. Jul 30 How to Incorporate the Patient Experience into Trials Sep 15 TransCelerate BioPharma in the NewsĪug 13 TransCelerate Launches New Blog: Accelerate to Innovate Nov 10 The Clinical Content & Reuse (CC&R) Team announces their 2020 release! Mar 05 Nimbleness and Innovation Are Top Themes at SCOPE 2021įeb 25 TransCelerate BioPharma in the Newsįeb 11 Despite the Pandemic, 2020 Brought Immense Innovation Across the Biopharmaceutical Research Ecosystemĭec 15 TransCelerate Launches Leadership Lens Video Seriesĭec 02 How the Pharmaceutical Community is Powering the Sharing and Reuse of Data Mar 11 How Shionogi and Bristol-Myers Squibb leverage data sharing to make data-driven decisions on compounds Mar 25 Validating Intelligent Automation Systems in Pharmacovigilance: Insights from Good Manufacturing Practice May 20 International Clinical Trials Day 2021: Rising to Drive Purposeful ChangeĪpr 21 Protocol Deviations: A Holistic Approach from Defining to Reporting Jul 06 DIA Global 2021: Innovation, Collaboration, and Transformation in BioPharma R&D Sep 13 Patient Technology: Innovating Clinical Trials with Novel Digital EndpointsĪug 27 TransCelerate Recent News and HappeningsĪug 03 Seven ways to diversify patient populations in clinical trials Oct 18 Driving better health outcomes: Joining hands to improve Diversity & Inclusion efforts in clinical trials Jan 04 TransCelerate BioPharma in the News Q4 2021 Jan 20 Driving Momentum: TransCelerate’s 2021 Year in Review Mar 08 Cross-Consortia Diversity Collaboration Landscape Assessment Launchesįeb 14 SCOPE 2022 shows great success for TransCelerate and our Members May 23 Learning From the Past as We Look to the FutureĪpr 28 TransCelerate BioPharma in the News Q1 2022Īpr 05 TransCelerate Shares Solution Insights During DIA Europe 2022 Jun 01 How TransCelerate, Microsoft, Accenture, and CDISC are Working to Revolutionize Digital Data Flow Jun 30 DIA Annual 2022 Marks A Return to In-Person Conferences Join Our Awareness & Implementation CommunityĪug 03 TransCelerate BioPharma in the News: Q2 2022. ![]() Value of Safety Information Data Sources.Pharmacovigilance Agreements Optimization. ![]() Interpretation of Pharmacovigilance Guidances & Regulations.Interpretation of Clinical Guidances & Regulations.Intelligent Automation Opportunities in Pharmacovigilance.Diversity of Participants in Clinical Trials.Common Serious Adverse Events (SAE) Fields.Clinical Research Access & Information Exchange. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |